Phase 2
N=4
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Multiple Myeloma
Bottom Line
View on ClinicalTrials.gov: NCT04436029 ↗Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Rate of Stringent Complete Response — 1 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Descartes 11 (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cartesian Therapeutics
- Primary completion
- Feb 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Stringent Complete Response |
1 | — |
Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
Eligibility Criteria
Inclusion Criteria
- Patients must be 18 years of age or older at the time of enrollment
- High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).
Exclusion Criteria
- Patients who are pregnant or lactating.
- Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.
Data sourced from ClinicalTrials.gov (NCT04436029). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.